Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 2434-2439, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saito, M.
Right arrow Articles by Tanaka, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saito, M.
Right arrow Articles by Tanaka, E.

Clinical Chemistry, Vol 38, 2434-2439, Copyright © 1992 by American Association for Clinical Chemistry

Performance of an enzyme-linked immunosorbent assay system for antibodies to hepatitis C virus with two new antigens (c11/c7)

M Saito, A Hasegawa, T Kashiwakuma, M Kohara, M Sugi, K Miki, T Yamamoto, H Mori, Y Ohta and E Tanaka
Tonen Corporation, Fundamental Research Laboratory, Saitama, Japan.

We developed an enzyme-linked immunosorbent assay (ELISA) system for antibodies to the hepatitis C virus (HCV), using two new recombinant antigens (c11 and c7) derived from the HCV genome. The performance of this ELISA system (Imucheck HCV Ab) was examined. The CV values for both intra-assay precision and reproducibility of identifying HCV antibody in the panel sera ranged from 3.5% to 6.4%. The blood elements in serum and anticoagulants did not interfere in this ELISA system. The specificity of Imucheck HCV Ab to samples from patients with non-A, non- B (NANB)-type chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma was 93.7%, 93.5%, and 81.4%, respectively. These results are more sensitive than those obtained by the first-generation anti-HCV ELISA system. In the samples from patients with NANB-type acute hepatitis, Imucheck HCV Ab enabled detection of HCV antibodies at an early stage. This system increased the sensitivity for blood donor screening and for monitoring patients with acute hepatitis.


The following articles in journals at HighWire Press have cited this article:


Home page
 ANN INTERN MEDHome page
R. Chou, E. C. Clark, and M. Helfand
Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, March 16, 2004; 140(6): 465 - 479.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
H. Tokita, G. R. Kaufmann, M. Matsubayashi, I. Okuda, T. Tanaka, H. Harada, M. Mukaide, K. Suzuki, and D. A. Cooper
Hepatitis C Virus Core Mutations Reduce the Sensitivity of a Fluorescence Enzyme Immunoassay
J. Clin. Microbiol., September 1, 2000; 38(9): 3450 - 3452.
[Abstract] [Full Text]

Home page
 J. Clin. Microbiol.Home page
K. Aoyagi, C. Ohue, K. Iida, T. Kimura, E. Tanaka, K. Kiyosawa, and S. Yagi
Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen
J. Clin. Microbiol., June 1, 1999; 37(6): 1802 - 1808.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.